Clinical Trials


Sponsor Study ID: EA2174

Study Title: A Phase II/III Study of Peri operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma

NCT Number: NCT03604991

Phase: II/III

Protocol Type: Treatment

Age Group: Adults

Disease Sites: Esophagus

Study Objectives: This phase II/III trial studies the usefulness of treatment with nivolumab and ipilimumab in addition to standard of care chemotherapy and radiation therapy in patients with esophageal and gastroesophageal junction adenocarcinoma who are undergoing surgery.

Study Documents    
(MUSC NetID required for document access)